A share price of CureVac N.V. [CVAC] is currently trading at $3.51, down -1.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The CVAC shares have gain 2.63% over the last week, with a monthly amount drifted -5.14%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, January 2024, CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform. In a post published today on Yahoo Finance, Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile.
From an analyst’s perspective:
CureVac N.V. [NASDAQ: CVAC] stock has seen the most recent analyst activity on June 08, 2023, when SVB Securities initiated its Outperform rating and assigned the stock a price target of $13. Previously, UBS upgraded its rating to Buy on January 19, 2023, and elevated its price target to $18. On January 09, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $21 on the stock. BofA Securities downgraded its rating to a Underperform and decreased its price target to $20 on January 21, 2022. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $52 as its price target on January 18, 2022. Deutsche Bank started tracking with a Hold rating for this stock on October 22, 2021, and assigned it a price target of $35. In a note dated June 17, 2021, BofA Securities downgraded an Neutral rating on this stock but restated the target price of $50.
CureVac N.V. experienced fluctuations in its stock price throughout the past year between $3.27 and $12.36. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. CureVac N.V. [NASDAQ: CVAC] shares were valued at $3.51 at the most recent close of the market. An investor can expect a potential return of 726.21% based on the average CVAC price forecast.
Analyzing the CVAC fundamentals
Trailing Twelve Months sales for CureVac N.V. [NASDAQ:CVAC] were 45.75M which represents 58.86% growth. Gross Profit Margin for this corporation currently stands at -2.52% with Operating Profit Margin at -7.18%, Pretax Profit Margin comes in at -7.05%, and Net Profit Margin reading is -7.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.48 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.44 points at the first support level, and at 3.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.60, and for the 2nd resistance point, it is at 3.68.
CureVac N.V. [CVAC] reported earnings per share of -$0.24 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.25/share, meaning a difference of $0.01 and a surprise factor of 4.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.33 per share as compared to estimates of -$0.26 per share, a difference of -$0.07 representing a surprise of -26.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CureVac N.V. [NASDAQ:CVAC] is 3.56. On the other hand, the Quick Ratio is 3.41, and the Cash Ratio is 3.08. Considering the valuation of this stock, the price to sales ratio is 17.18, the price to book ratio is 1.23.
